

Press Release

2024 October 29th

HTL Biotechnology achieves Halal certification for its products reinforcing its commitment to international customers

[Javené, October 29, 2024] - HTL Biotechnology, world leader in the development and bioproduction of pharmaceutical-grade biopolymers, announces that two of its key products, polynucleotides (PN and PDRN) and hyaluronic acid (HA), have obtained Halal certification, a recognition that attests to the company's commitment to its customers.

By obtaining this certification, HTL Biotechnology is meeting market requirements and taking a further step towards inclusiveness. Halal certification is a mark of confidence for customers, guaranteeing that our products meet the strict requirements of the Muslim religion.

Asia is home to a large and diverse Muslim population. This certification is of particular importance to our customers in Asia, a region where demand for halal-certified products is constantly growing. By obtaining halal certification, HTL Biotechnology not only meets the expectations of these customers, but also strengthens its position in these strategic markets.

“Halal certification has become a major issue. Many of our customers in Korea export their products to Southeast Asia and the Middle East, regions where 60-70% of the

Muslim population live. Beyond the production of our biopolymers, we attach great importance to the quality of our services provided to our customers, and this certification is an illustration of that. This certification brings real added value to our customers.”, says Marie-Armelle Floc'h, Chief Quality and Compliance Officer.

About HTL Biotechnology

HTL Biotechnology is a French biotech and a world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers (Hyaluronic acid, polynucleotides). These biopolymers are used by healthcare companies for the development of treatments in various cutting-edge therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology.

For over 30 years, HTL Biotechnology has been a driving force behind innovation in the sector, collaborating with research entities and biotech companies to address unmet medical needs (regenerative medicine, drug delivery, etc.) HTL Biotechnology recently reinforced its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) within a world-class scientific research center.

To meet growing global needs for biopolymers, the company has also subsidiaries in Asia and is building in the United States, a neuromodulator production unit (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, research and development, as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide.

To know more on HTL Biotechnology: <https://htlbiotech.com/ko/>

Press Contact

Nathalie Chevallon - HTL

nchevallon@htlbiotech.com

+33 7 61 45 26 85